New shot shows promise in fight against chronic hepatitis b
NCT ID NCT07190742
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 27 times
Summary
This study tests an experimental injection called TVAX-008 in 80 adults with chronic hepatitis B who are already taking antiviral pills. Half receive the injection and half receive a placebo for 24 weeks, then some may continue with TVAX-008 for another 24 weeks. The goal is to see if TVAX-008 can help clear the hepatitis B surface antigen (HBsAg) and better control the virus.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B VIRUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University first hospital
Beijing, 10000, China
Conditions
Explore the condition pages connected to this study.